Company Overview and News
New Delhi: The Supreme Court on Thursday refused to pass any interim order to permit banks to sell shares pledged by Malvinder Singh and Shivinder Singh in Fortis Healthcare Holding Pvt. Ltd. (17-0)
New Delhi: Religare Enterprises Ltd, promoted by brothers Shivinder Singh and Malvinder Singh, told on Wednesday the Delhi high court that the sale of its health insurance business is unlikely to happen this year. (4-0)
New Delhi: The Supreme Court on Friday directed former Ranbaxy promoters, Malvinder and Shivender Singh, to maintain status quo with regard to their stake in Fortis Healthcare Ltd.
India Ratings has downgraded NCDs of RHC Holding at a time when Singh brothers are in talks with banks to meet repayment obligations of Religare Enterprises
Fortis Healthcare Holdings has been selling its unencumbered assets without applying to the court, says Daiichi Sankyo
The Delhi High Court on Tuesday asked RHC Holdings and Oscar Investments (companies owned by former Ranbaxy promoters Malvinder and Shivinder Singh) to respond by August 10 to a contempt application filed against them by Japanese pharmaceutical major Daiichi Sankyo.
The order to allow conditional stake sale by Singh brothers in Fortis Healthcare was passed to afford protection to Daiichi Sankyo in terms of ready realizable value of assets at a later stage
IHH Healthcare to buy 26% stake in Fortis from Malvinder and Shivinder Singh; both sides agree to a combined $2.9 billion valuation for Fortis and SRL Diagnostics
Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.
Daiichi Sankyo approached the Delhi High Court on Monday to protest against the 80 percent stake sale of Religare Health Insurance by former Ranbaxy promoter's Malvinder and Shivinder Singh. The objection to the April 9 sale of Religare's insurance business with private equity fund True North Managers marks Daiichi's latest attempt at securing the assets of the Singh brothers for the realisation of a Rs 2,562 crore Singapore arbitration award in favour of the Japanese pharmaceutical major.
The latest turn in a long running legal brawl with Daiichi Sankyo means Shivinder Singh and Malvinder Singh can’t change the status of their holdings without first getting permission from the Delhi high court
MUMBAI (March 28): India’s Singh brothers are serial entrepreneurs known for pulling off one of the best-timed exits in the annals of Indian business.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
Daiichi Sankyo made its fourth attempt in the Delhi High Court on Monday to secure the assets of Malvinder Singh and Shivinder Singh (and their affiliate companies), after claiming that the former Ranbaxy promoters had made false statements in earlier affidavits tendered before the court. The affidavits in question had been submitted by the Singh brothers in line with directions issued on a petition seeking the enforcement of a Rs 2,562 crore Singapore arbitral award in favour of the Japanese pharma major.
An arbitration court in Singapore has ordered Malvinder Singh and Shivinder Mohan Singh, former owners of Ranbaxy Laboratories, to pay damages worth Rs 2,562.78 crore (based on Thursday's exchange rate) to Japan's Daiichi Sankyo Co. Malvinder Singh, currently chairman of Fortis Healthcare, and his brother Shivinder Singh will have to pay the fine for concealing and misrepresenting facts from the Japanese drug giant when it purchased about 35 per cent stake in Ranbaxy from them in 2008.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton